|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0014582,
umls-concept:C0178602,
umls-concept:C0278488,
umls-concept:C0282461,
umls-concept:C0442805,
umls-concept:C0444956,
umls-concept:C0522510,
umls-concept:C0871261,
umls-concept:C1257890,
umls-concept:C1319266,
umls-concept:C1512888,
umls-concept:C1521828,
umls-concept:C1704632,
umls-concept:C1705764,
umls-concept:C1706817,
umls-concept:C1880654,
umls-concept:C2603343,
umls-concept:C2911692
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1997-6-5
|
|
pubmed:abstractText |
A phase III study was performed in patients with metastatic breast cancer (MBC) to evaluate the effect on response rate and survival of a doubling of the epirubicin dose intensity.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
155-62
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:9093724-Adult,
pubmed-meshheading:9093724-Aged,
pubmed-meshheading:9093724-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9093724-Breast Neoplasms,
pubmed-meshheading:9093724-Cyclophosphamide,
pubmed-meshheading:9093724-Drug Administration Schedule,
pubmed-meshheading:9093724-Epirubicin,
pubmed-meshheading:9093724-Female,
pubmed-meshheading:9093724-Fluorouracil,
pubmed-meshheading:9093724-Humans,
pubmed-meshheading:9093724-Middle Aged,
pubmed-meshheading:9093724-Stroke Volume,
pubmed-meshheading:9093724-Treatment Outcome,
pubmed-meshheading:9093724-Ventricular Function, Left
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group.
|
|
pubmed:affiliation |
Hadassah Medical Centre Ein Karem, Jerusalem, Israel.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
